Efficacy and safety of continuous 4-year telbivudine treatment in patients with chronic hepatitis B

• المؤلفون الرئيسيون: Wang Y., Thongsawat S., Gane E.J., Liaw Y.-F., Jia J., Hou J., Chan H.L.Y., Papatheodoridis G., Wan M., Niu J., Bao W., Trylesinski A., Naoumov N.V.
• التنسيق: مقال
• اللغة: English
• منشور في: 2014
• الوصول للمادة أونلاين: http://www.scopus.com/inward/record.url?eid=2-s2.0-84875229260&partnerID=40&md5=1eda83af67c7ccfd0971bbc62d162056; http://www.ncbi.nlm.nih.gov/pubmed/23490388; http://cmuir.cmu.ac.th/handle/6653943832/4045

In the phase-III GLOBE/015 studies, telbivudine demonstrated superior efficacy vs lamivudine during 2-year treatment in HBeAg-positive and HBeAg-negative chronic hepatitis B (CHB). After completion, 847 patients had an option to continue telbivudine treatment for further 2 years. A total of 596 (70%...